HORSHAM, Pa. and KENILWORTH, N.J., April 13 - Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) today announced that Health Canada has grant -- In combination with methotrexate ...

First Anti-TNF Infusion Therapy Approved in More Than a Decade for Patients Living with Moderately to Severely Active Rheumatoid Arthritis "Phase 3 data showed treatment with SIMPONI ARIA plus ...

Please provide your email address to receive an email when new articles are posted on . Alvotech’s AVT05 showed therapeutic equivalence with golimumab in DAS28-CRP score change at 16 weeks. The ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Janssen Biotech announced that the FDA ...

Alvotech (NASDAQ:ALVO) said it has started a pharmacokinetic study for AVT05, a biosimilar of Johnson & Johnson's drug Simponi and Simponi Aria (golimumab). Simponi is used to treat certain types of ...

April 27, 2009 — The US Food and Drug Administration (FDA) has approved golimumab (Simponi, Centocor Ortho Biotech Inc) for monthly subcutaneous injection in the treatment of adults with ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

HORSHAM, Pa., Sept. 27 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration ...

The FDA's expanded approvals were supported by data from two Phase 3 multicenter, randomized, double-blind, placebo-controlled studies (GO-VIBRANT and GO-ALIVE) that included >600 patients. Janssen ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its TNF inhibitor, Simponi Aria for the treatment of children 2 years and older with active polyarticular course juvenile ...